Unrest sowed by Incyte Corp.'s futility-driven stoppage of a phase II substudy testing Jakafi (ruxolitinib) and Stivarga (regorafenib, Bayer AG) against metastatic colorectal cancer (mCRC) helped drive company shares (NASDAQ:INCY) down 9.6 percent on Thursday, closing at $67.81, as analysts pondered the implications for a phase III test of Jakafi in metastatic pancreatic cancer that is expected to yield results this year.